The United States Food and Drug Administration (FDA) has completed the implementation of its proprietary generative AI platform Elsa, designed to modernize internal operations. According to FDA Commissioner Marty Makary, Elsa now performs tasks that previously required up to three days in just six minutes. The platform is hosted within the secure GovCloud environment, ensuring a high level of data security.
Elsa is intended for data processing and analysis, including summarizing incident reports, comparing drug labels, and identifying high-risk areas. All data remains within the agency, and the models are not trained on external industry datasets, ensuring adherence to strict security standards.
The implementation of Elsa is part of a broader FDA strategy to integrate artificial intelligence into its operations, in line with the White House’s April directive encouraging federal agencies to actively adopt AI technologies.
